Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Sigrid S. Skånland, Anthony R. Mato
Blood Advances (2021) Vol. 5, Iss. 1, pp. 334-343
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski
Cancers (2022) Vol. 14, Iss. 3, pp. 771-771
Open Access | Times Cited: 47
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Sigrid S. Skånland, Jennifer R. Brown
Haematologica (2022) Vol. 108, Iss. 1, pp. 9-21
Open Access | Times Cited: 28
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Alexandra Chirino, Skye Montoya, Anita Safronenka, et al.
Genes (2023) Vol. 14, Iss. 12, pp. 2182-2182
Open Access | Times Cited: 19
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease
Garth Powis, Emmanuelle J. Meuillet, Martín Indarte, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115024-115024
Open Access | Times Cited: 18
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples
Jasneet Kaur Khalsa, Justin Cha, Filippo Utro, et al.
Blood (2023) Vol. 142, Iss. 5, pp. 421-433
Open Access | Times Cited: 15
PI3K inhibitors in hematology: When one door closes…
Sigrid S. Skånland, Klaus Okkenhaug, Matthew S. Davids
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3667-3675
Closed Access | Times Cited: 5
Drug resistance in human cancers — Mechanisms and implications
Sudikshaa Vijayakumar, Raveena Dhakshanamoorthy, Akshaya Baskaran, et al.
Life Sciences (2024) Vol. 352, pp. 122907-122907
Closed Access | Times Cited: 5
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial
Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, et al.
Blood (2023) Vol. 143, Iss. 1, pp. 57-63
Open Access | Times Cited: 12
γδ T Are Significantly Impacted by CLL Burden but Only Mildly Influenced by M-MDSCs
Michał Zarobkiewicz, Wioleta Kowalska, Agata Szymańska, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 254-254
Open Access
Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)
Julia H. Aronson, Sigrid S. Skånland, Lindsey E. Roeker, et al.
American Journal of Hematology (2022) Vol. 97, Iss. S2
Open Access | Times Cited: 17
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
Johanne U. Hermansen, Yanping Yin, Aleksandra Urban, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Hanbyeol Kim, Jeongbae Park, Jeong‐Mok Kim
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2100-2100
Open Access | Times Cited: 15
From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct
Isabel González-Gascón-y-Marín, Carolina Muñoz‐Novas, Ana‐Eugenia Rodríguez‐Vicente, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1782-1782
Open Access | Times Cited: 18
CD160 receptor in CLL: Current state and future avenues
Loubna Oumeslakht, Abdel-ilah Aziz, Armand Bensussan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
Christian Sordo‐Bahamonde, Seila Lorenzo‐Herrero, Alejandra Martínez‐Pérez, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2529-2539
Open Access | Times Cited: 6
The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
Marta Sampietro, Valeria Cassina, Domenico Salerno, et al.
HemaSphere (2023) Vol. 7, Iss. 8, pp. e931-e931
Open Access | Times Cited: 6
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
R Joseph, Thomas E. Wales, Sandrine Jayne, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 2
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies
Katrine Melvold, Mariaserena Giliberto, Linda Karlsen, et al.
Molecular Oncology (2021) Vol. 16, Iss. 5, pp. 1153-1170
Open Access | Times Cited: 15
Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case
Sigrid S. Skånland, Marit Inngjerdingen, Henrik Bendiksen, et al.
Haematologica (2022) Vol. 107, Iss. 8, pp. 1994-1998
Open Access | Times Cited: 10
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia
Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6712-6712
Open Access | Times Cited: 10
Extracellular Vesicles in Chronic Lymphocytic Leukemia: Tumor Microenvironment Messengers as a Basis for New Targeted Therapies?
Kenza Dubois, Mariana Tannoury, Brigitte Bauvois, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2307-2307
Open Access | Times Cited: 6
Determining drug dose in the era of targeted therapies: playing it (un)safe?
Sigrid S. Skånland, Geir E. Tjønnfjord
Blood Cancer Journal (2022) Vol. 12, Iss. 8
Open Access | Times Cited: 9
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 20, pp. 4444-4455
Open Access | Times Cited: 9
Sequencing and combination of current small‐molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence?
Clement Chung, Godsfavour Umoru, Karen Abboud, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 1, pp. 15-28
Open Access | Times Cited: 5
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells
Chuanyou Xia, Laia Sadeghi, Klas Strååt, et al.
Prostaglandins & Other Lipid Mediators (2021) Vol. 156, pp. 106575-106575
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top